Pfizer Inc. stock gains as updated COVID vaccine fuels valuation debate

Pfizer Inc. stock has advanced in recent weeks amid approval of an updated COVID-19 vaccine, with the share price near 29 dollars and valuation metrics now described as stretched by some analysts.

Pfizer Inc. (ISIN US7170811035) stock is trading close to 29.00 USD as of September 3, 2026, after a double-digit move since its last earnings report, putting fresh attention on how far the rally can go according to market data.

Valuation runs ahead of earnings

According to an analysis published on September 4, 2026, Pfizer currently trades on a price-to-earnings ratio of 37.8x, compared with a Pharmaceuticals industry average of 16.3x and a peer group average of 56.4x, indicating that Pfizer stock is more than double the broader industry multiple on this metric while still below some high-growth peers. The same assessment points to a fair P/E ratio of 28.4x for Pfizer, suggesting that the existing 37.8x level leaves the shares screening as overvalued on an earnings basis even after accounting for peer comparisons.

A separate performance review dated September 3, 2026 notes that Pfizer stock has risen 12.4 percent since the company released its most recent earnings report, underlining that the market has rewarded recent developments but also compressing forward returns if earnings do not accelerate materially from here.

Stock performance and price context

Market data from a European stock portal for Pfizer Inc. shows a last closing price of 28.81 USD on the New York Stock Exchange as of September 3, 2026, with a minor decline of 0.72 percent on that trading day. The same quote overview indicates an after-hours indication of 28.86 USD, representing a 0.16 percent uptick following the regular session, which keeps Pfizer stock narrowly above the latest official close while still near the 29 dollar mark.

Using the 28.81 USD closing price as of September 3, 2026, the 12.4 percent rise since the last earnings report implies that Pfizer shares have moved up from roughly the mid-25 USD area in recent weeks, a recovery that investors are now weighing against the elevated P/E multiple and the company’s pipeline progress.

Updated COVID-19 vaccine as a catalyst

A key current operational driver for Pfizer is its updated COVID-19 vaccine, developed with BioNTech and adapted to target the XFG subvariant for the 2026-27 season. A recent report from an Australian news outlet dated September 4, 2026 notes that this latest Pfizer and BioNTech vaccine has been approved in the United States for the 2026-27 vaccination season, in line with international guidance to better align vaccines with contemporary circulating variants.

In the same coverage, it is highlighted that this new XFG-adapted vaccine has not yet been registered for use in Australia, even though Pfizer’s earlier LP.8.1-adapted vaccine is already registered there for people aged six months and older. The staggered geographical rollout underscores how regulatory timing can influence regional revenue contributions, even when a product is cleared in a major market such as the United States.

Representative product and revenue relevance

Pfizer’s updated COVID-19 vaccine targeting the XFG subvariant is a representative product for the group’s vaccine segment and remains central to revenue trends in the post-pandemic environment. While the latest articles focus on approval status and registration in different countries rather than explicit quarterly revenue figures, the positioning for the 2026-27 season indicates that vaccine income will continue to contribute meaningfully to Pfizer’s pharmaceutical portfolio alongside its other therapeutic areas.

Stock price and investor perspective

Pfizer Inc. stock closed at 28.81 USD on the New York Stock Exchange as of September 3, 2026, with an after-hours indication of 28.86 USD referenced in the same market overview, leaving the shares modestly higher than the last official close and near the 29 dollar level that has become a short-term reference point for investors.

Pfizer Inc. key data

• Company: Pfizer Inc.
• ISIN: US7170811035
• Ticker: PFE
• Trading venue: NYSE
• Price (as of September 3, 2026): 28.81 USD
• Sector / Industry: Pharmaceuticals / Biotechnology
• Index membership: S&P 500